Operator
Hi there, everybody, and a heat welcome once more to the Poland convention on air to those that attended some additional calls. And now I am delighted to welcome FamiCord AG and the CEO, Jakub Baran. So he would be the final presentation, however not the least. So now we’re blissful to see what FamiCord is doing. And sure, you’re going to get us by way of some insights and the presentation, Jakub. So now the stage is yours.
Jakub Baran
Chairman of the Administration Board & CEO
Thanks — thanks very a lot. Welcome, all people. This time from our Warsaw workplace. I share my time between Leipzig and Warsaw. And I’ll inform you, I’ll stroll you thru a presentation of our firm named FamiCord, which we imagine is simply one thing greater than stem cell financial institution.
So to begin with, why we’re right here at Poland ON AIR. A couple of years in the past, Polish firm referred to as komorek macierzystych did a cross-border merger with German listed firm referred to as Vita 34 AG. And Vita on the time was listed at Deutsche Borse and we’re listed on the Warsaw Inventory Alternate. So on the time, Vita merely bought PBKM, paying in shares and partially in money. The truth is, that transaction was a reversal takeover as PBKM was a lot bigger firm on the time and was by far the biggest stem cell financial institution in Europe.
After that merger, which is fairly uncommon, and we expect it is slightly even distinctive operations between mid-cap firms between Polish and German inventory exchanges, PBKM was delisted from Warsaw Inventory Alternate, and now we’re listed solely at
